Skip to main content
Fig. 9 | Molecular Neurodegeneration

Fig. 9

From: Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

Fig. 9

Mean serum concentrations and pharmacokinetics parameters of Armanezumab following a single IV dose to PS19 tau/Tg and C57BL6 mice. Error bars represent average ± SD (n = 3 for C57BL6 and n = 9 for PS19 tau/Tg groups). Pharmacokinetic analyses were performed as described in Materials and Methods. Kel, elimination constant; T-1/2, elimination half-life; Tmax, the time to reach max concentration; Cmax, the maximum concentration; AUC 0-t, area under the concentration-time curve; AUC 0-inf, the area to infinity; AUC 0-inf %extrap, % of extrapolated AUC to infinity; Vd, the apparent volume of distribution

Back to article page